RESUMEN
Los niños con lesiones selares y/o supraselares pueden presentar diabetes insípida central con posterior secreción inadecuada de hormona antidiurética. Nosotros observamos, en algunos casos, aumento de la incidencia de poliuria, natriuresis e hiponatremia, tríada diagnóstica del síndrome cerebral perdedor de sal. Aquí comunicamos la evolución de 7 pacientes con antecedentes de daño agudo del sistema nervioso central y diabetes insípida central seguida por síndrome cerebral perdedor de sal. Como tratamiento aportamos secuencialmente fluidos salinos parenterales, cloruro de sodio oral, desmopresina, mineralocorticoides e incluso tiazidas. Ante la persistencia de poliuria con hiponatremia, agregamos ibuprofeno. Como resultado de este esquema terapéutico secuencial, este grupo redujo significativamente los valores de diuresis diaria de 10 ml/kg/h a 2 ml/kg/h en un tiempo promedio de 5 días, normalizando también las natremias (de 161 mEq/L a 143 mEq/L) en un tiempo promedio de 9 días. En ningún caso observamos efectos adversos asociados al tratamiento.
Children with sellar and/or suprasellar lesions may develop central diabetes insipidus with subsequent inappropriate antidiuretic hormone secretion. An increased incidence of polyuria, natriuresis, and hyponatremia has been reported in some cases, which make up the diagnostic triad of cerebral salt wasting syndrome. Here we report the clinical course of 7 patients with a history of acute central nervous system injury and central diabetes insipidus followed by cerebral salt wasting syndrome. Treatment included the sequential use of parenteral saline solution, oral sodium chloride, desmopressin, mineralocorticoids, and even thiazides. Due to persistent polyuria and hyponatremia, ibuprofen was added. As a result of this sequential therapeutic regimen, daily urine output reduced significantly from 10 mL/ kg/h to 2 mL/kg/h over an average period of 5 days, together with a normalization of natremia (from 161 mEq/L to 143 mEq/L) over an average period of 9 days. No treatment-related adverse effects were observed in any case.
Asunto(s)
Humanos , Preescolar , Niño , Adolescente , Diabetes Insípida Neurogénica , Hiponatremia/etiología , Hiponatremia/tratamiento farmacológico , Poliuria/complicaciones , Poliuria/etiología , Investigación , Ibuprofeno/uso terapéuticoRESUMEN
Children with sellar and/or suprasellar lesions may develop central diabetes insipidus with subsequent inappropriate antidiuretic hormone secretion. An increased incidence of polyuria, natriuresis, and hyponatremia has been reported in some cases, which make up the diagnostic triad of cerebral salt wasting syndrome. Here we report the clinical course of 7 patients with a history of acute central nervous system injury and central diabetes insipidus followed by cerebral salt wasting syndrome. Treatment included the sequential use of parenteral saline solution, oral sodium chloride, desmopressin, mineralocorticoids, and even thiazides. Due to persistent polyuria and hyponatremia, ibuprofen was added. As a result of this sequential therapeutic regimen, daily urine output reduced significantly from 10 mL/kg/h to 2 mL/kg/h over an average period of 5 days, together with a normalization of natremia (from 161 mEq/L to 143 mEq/L) over an average period of 9 days. No treatment-related adverse effects were observed in any case.
Los niños con lesiones selares y/o supraselares pueden presentar diabetes insípida central con posterior secreción inadecuada de hormona antidiurética. Nosotros observamos, en algunos casos, aumento de la incidencia de poliuria, natriuresis e hiponatremia, tríada diagnóstica del síndrome cerebral perdedor de sal. Aquí comunicamos la evolución de 7 pacientes con antecedentes de daño agudo del sistema nervioso central y diabetes insípida central seguida por síndrome cerebral perdedor de sal. Como tratamiento aportamos secuencialmente fluidos salinos parenterales, cloruro de sodio oral, desmopresina, mineralocorticoides e incluso tiazidas. Ante la persistencia de poliuria con hiponatremia, agregamos ibuprofeno. Como resultado de este esquema terapéutico secuencial, este grupo redujo significativamente los valores de diuresis diaria de 10 ml/kg/h a 2 ml/kg/h en un tiempo promedio de 5 días, normalizando también las natremias (de 161 mEq/L a 143 mEq/L) en un tiempo promedio de 9 días. En ningún caso observamos efectos adversos asociados al tratamiento.
Asunto(s)
Diabetes Insípida Neurogénica , Hiponatremia , Humanos , Niño , Hiponatremia/tratamiento farmacológico , Hiponatremia/etiología , Poliuria/etiología , Poliuria/complicaciones , Ibuprofeno/uso terapéutico , InvestigaciónRESUMEN
BACKGROUND: Shiga toxin-producing Escherichia coli (STEC) infection is the most common cause of hemolytic uremic syndrome (HUS). Only few studies correlated serotypes and stx genotypes with disease severity. This study aimed to update STEC serotypes, stx genotypes, and virulence factors (eae and ehxA) in a cohort of patients with STEC-HUS and investigate whether they influence the severity of disease. METHODS: In this multicentric study, children hospitalized between 2005 and 2016 with STEC-HUS confirmed by the National Reference Laboratory were included. Serotypes (O157, O145, O121, and others), stx genotypes (stx1a, stx2a, stx2c, stx2d, and others), and virulence factors were analyzed, and their association with dialysis requirement (>10 days); severe neurological, cardiovascular, and/or bowel involvement; and death was assessed. RESULTS: The records of 280 patients were reviewed; 160 females, median age 21 months (IQR18m). STEC O157 was isolated in 206 (73.6%) patients, O145 in 47 (16.8%), O121 in 15 (5.4%), and other serotypes in 12 (4.2%). The stx2a/2c genotype was carried by 179 (63.9%) strains, stx2a by 94 (33.6%), stx1a/stx2a by five (1.8%), and stx1a only by two (0.7%). All strains except six harbored eae and ehxA genes. Fifty-nine (21.1%) patients had severe neurological involvement, 29 (10.4%) severe bowel injury, 14 (5%) cardiovascular involvement, 53 (18.9%) required > 10 days of dialysis, and 12 (4.3%) died. Neither serotypes nor stx genotypes detected were significantly linked to severity. CONCLUSIONS: Serotype O157 and virulence stx2a/2c, eae, ehxA genotype are prevalent in Argentina, and no relationship was found between severity and serotypes and genotypes of STEC detected.
Asunto(s)
Infecciones por Escherichia coli , Síndrome Hemolítico-Urémico , Escherichia coli Shiga-Toxigénica , Argentina/epidemiología , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/epidemiología , Proteínas de Escherichia coli/genética , Femenino , Genotipo , Síndrome Hemolítico-Urémico/epidemiología , Síndrome Hemolítico-Urémico/etiología , Humanos , Lactante , Masculino , Diálisis Renal , Serogrupo , Escherichia coli Shiga-Toxigénica/genética , Factores de Virulencia/genéticaRESUMEN
La gangrena de Fournier es una fascitis necrotizante que afecta las regiones genital, perineal y perianal, de inicio súbito y diseminación rápidamente progresiva. Su diagnóstico obliga a una urgente intervención interdisciplinaria. La asociación con enfermedades nefrológicas es rara.Se presenta un caso de gangrena de Fournier en un niño con síndrome nefrótico corticorresistente y anasarca con edema escrotal grave. Recibió un esquema antibiótico de amplio espectro y se realizó un desbridamiento quirúrgico extenso e inmediato de la lesión necrótica. Posteriormente, requirió reparación por parte de Cirugía Plástica. Presentó una respuesta clínica favorable a la terapéutica instaurada.
Fournier gangrene is a necrotizing fasciitis that affects the genital, perineal and perianal regions, of sudden onset and rapidly progressive dissemination. Its diagnosis requires an urgent and interdisciplinary intervention. The association with nephrologic diseases is rare.We present a case of Fournier gangrene in a child with steroid-resistant nephrotic syndrome and anasarca with severe scrotal edema. He received a broad-spectrum antibiotic scheme and extensive an immediate surgical debridement of the necrotic lesion was carried out. Subsequently, it was repaired by Plastic Surgery. He presented a favourable clinical response
Asunto(s)
Humanos , Masculino , Preescolar , Gangrena de Fournier/cirugía , Gangrena de Fournier/diagnóstico , Fascitis Necrotizante , Edema , Enfermedades de los Genitales Masculinos , Antibacterianos/uso terapéutico , Síndrome NefróticoRESUMEN
Fournier gangrene is a necrotizing fasciitis that affects the genital, perineal and perianal regions, of sudden onset and rapidly progressive dissemination. Its diagnosis requires an urgent and interdisciplinary intervention. The association with nephrologic diseases is rare. We present a case of Fournier gangrene in a child with steroidresistant nephrotic syndrome and anasarca with severe scrotal edema. He received a broad-spectrum antibiotic scheme and extensive an immediate surgical debridement of the necrotic lesion was carried out. Subsequently, it was repaired by Plastic Surgery. He presented a favourable clinical response.
La gangrena de Fournier es una fascitis necrotizante que afecta las regiones genital, perineal y perianal, de inicio súbito y diseminación rápidamente progresiva. Su diagnóstico obliga a una urgente intervención interdisciplinaria. La asociación con enfermedades nefrológicas es rara. Se presenta un caso de gangrena de Fournier en un niño con síndrome nefrótico corticorresistente y anasarca con edema escrotal grave. Recibió un esquema antibiótico de amplio espectro y se realizó un desbridamiento quirúrgico extenso e inmediato de la lesión necrótica. Posteriormente, requirió reparación por parte de Cirugía Plástica. Presentó una respuesta clínica favorable a la terapéutica instaurada.
Asunto(s)
Gangrena de Fournier/diagnóstico , Gangrena de Fournier/etiología , Síndrome Nefrótico/complicaciones , Antiinflamatorios/uso terapéutico , Preescolar , Humanos , Masculino , Síndrome Nefrótico/tratamiento farmacológico , Prednisona/análogos & derivados , Prednisona/uso terapéuticoRESUMEN
OBJECTIVES: (1) Evaluate mortality rate in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome, (2) determine the leading causes of death, and (3) identify predictors of mortality at hospital admission. METHODS: We conducted a multicentric, observational, retrospective, cross-sectional study. It included patients under 18 years old with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome hospitalized between January 2005 and June 2016. Clinical and laboratory data were obtained from the Argentine National Epidemiological Surveillance System of Hemolytic Uremic Syndrome. Clinical and laboratory variables were compared between deceased and non-deceased patients. Univariate and multivariate analyses were performed. ROC curves and area under the curve were obtained. RESULTS: Seventeen (3.65%) out of the 466 patients died, being central nervous system involvement the main cause of death. Predictors of death were central nervous system involvement, the number of days since the beginning of diarrhea to hospitalization, hyponatremia, high hemoglobin, high leukocyte counts, and low bicarbonate concentration on admission. In the multivariate analysis, central nervous system involvement, sodium concentration, and hemoglobin were independent predictors. The best cut off for sodium was ≤ 128 meq/l and for hemoglobin ≥ 10.8 g/dl. CONCLUSIONS: Mortality was low in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome, being central nervous system involvement the main cause of death. The best mortality predictors found were central nervous system involvement, hemoglobin, and sodium concentration. Hyponatremia may be a new Shiga toxin-producing Escherichia coli hemolytic uremic syndrome mortality predictor.
Asunto(s)
Infecciones por Escherichia coli/mortalidad , Síndrome Hemolítico-Urémico/mortalidad , Hiponatremia/mortalidad , Enfermedades del Sistema Nervioso/mortalidad , Escherichia coli Shiga-Toxigénica/aislamiento & purificación , Preescolar , Estudios Transversales , Infecciones por Escherichia coli/sangre , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/microbiología , Femenino , Hemoglobinas/análisis , Síndrome Hemolítico-Urémico/sangre , Síndrome Hemolítico-Urémico/complicaciones , Síndrome Hemolítico-Urémico/microbiología , Humanos , Hiponatremia/sangre , Hiponatremia/diagnóstico , Hiponatremia/etiología , Lactante , Masculino , Enfermedades del Sistema Nervioso/sangre , Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/etiología , Pronóstico , Curva ROC , Estudios Retrospectivos , Medición de Riesgo , Sodio/sangreRESUMEN
BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder caused by α-galactosidase enzyme deficiency. We present clinical, biochemical, and histologic findings in children with classical phenotypic presentation of Fabry disease. METHODS: A retrospective analysis was performed using charts from 14 children with confirmed diagnosis. Clinical parameters were evaluated. Globotriaosylsphingosine -lysoGb3- detection in plasma, podocyturia, and kidney biopsy were carried out in all cases. RESULTS: All patients except one demonstrated at least one symptom of Fabry disease. LysoGb3 levels were above the normal range in all patients. Podocyturia was documented in all patients. Kidney biopsy revealed glomerular, interstitial, vascular, and tubular changes on light microscopy in nearly all patients. Electron microscopy showed podocyte inclusions in all patients. CONCLUSIONS: No difference in symptomatology was discernible between boys and girls. Podocyturia was detectable in children serving as a possible early marker of kidney injury. LysoGb3 was elevated in all cases, emphasizing the importance for diagnosis especially in female patients with normal αGal A activity. A possible association between lysoGb3 and symptom severity and histological involvement in kidney biopsy should be assessed in prospective studies with enough statistical power to determine if lysoGb3 can be used to predict nephropathy in children with Fabry disease.
Asunto(s)
Enfermedad de Fabry/complicaciones , Glucolípidos/sangre , Enfermedades Renales/patología , Podocitos/patología , Esfingolípidos/sangre , Orina/citología , Adolescente , Biopsia , Niño , Preescolar , Enfermedad de Fabry/sangre , Enfermedad de Fabry/orina , Femenino , Humanos , Enfermedades Renales/sangre , Enfermedades Renales/etiología , Enfermedades Renales/orina , Masculino , Microscopía Electrónica , Podocitos/ultraestructura , Estudios Retrospectivos , Factores SexualesRESUMEN
Resumen: Introducción: En el síndrome nefrótico cortico-sensible (SNCS), la corticoterapia prolongada podría reducir la frecuencia de recaídas. El objetivo de este trabajo fue la comparación de un esquema corticoide prolongado frente al tratamiento habitual del SNCS primario, evaluando los siguientes parámetros: el número de pacientes con recaídas, el número total de recaídas, el tiempo medio transcurrido al iniciar el tratamiento, hasta la remisión y hasta la primera recaída, la dosis acumulada de corticosteroides y la toxicidad esteroide. Métodos: La población se dividió en dos grupos: el grupo A (27 pacientes) recibió 16-β-metilprednisona durante 12 semanas, reduciendo la dosis hasta la semana 24; y el grupo B (29 pacientes) recibió 16-β-metilprednisona durante 12 semanas, y placebo hasta la semana 24. Resultados: La tasa de incidencia acumulada de recaídas (persona/año) fue en el grupo A 36/100, y en el grupo B 66/100 (p = 0.04). El tiempo medio transcurrido (días) hasta la primera recaída fue de 114 en el grupo A y 75 en el grupo B (p = 0.01). Las diferencias de tiempo transcurrido al iniciar tratamiento y hasta la remisión entre ambos grupos no fueron significativas. El total acumulado de recaídas fue de 9 en el grupo A y 17 en el grupo B (p = 0.04), y el total de pacientes con recaídas fue de 3 (grupo A) y 7 (grupo B) (p = 0.17). La dosis media acumulada (mg/m2) por paciente fue de 5,243 en el grupo A y de 4,306 en el grupo B (p = 0.3), y el cortisol sérico (μg/dl) final fue de 14 en el grupo A y 16 en el grupo B (p = 0.4). La toxicidad esteroide fue similar entre ambos grupos. Conclusiones: La duración del tratamiento disminuyó el número de recaídas, sin incrementar la toxicidad esteroide.
Abstract: Background: In the steroid-sensitive nephrotic syndrome (SSNS) the prolonged treatment with steroids could decrease the frequency of relapses. We conducted a comparative study of prolonged steroid scheme and the usual treatment of primary SSNS to assess: the number of patients with relapses, mean time to treatment initiation, to remission and to first relapse, total number of relapses, total cumulative dose of steroids, and the steroid toxicity. Methods: Patients were divided into two groups: group A (27 patients) received 16-β-methylprednisolone for 12 weeks, reducing the steroid until week 24. Group B (29 patients) received 16-β-methylprednisolone for 12 weeks and placebo until week 24. Results: Cumulative incidence rate of relapse (person/years) for group A was of 36/100 and 66/100 for group B (p = 0.04). Average elapsed time to first relapse was of 114 days for group A and of 75 days to for group B (p = 0.01). The difference in time for initial response to treatment and up to achieve remission between both groups was not significant. Total cumulative relapses were 9 for group A and 17 for group B (p = 0.04). Total patients with relapses were 3 for group A and 7 for group B (p = 0.17). Cumulative average dose per patient was 5,243 mg/m2 for group A and 4,306 mg/m2 for group B (p = 0.3), and serum cortisol was 14 μg/dl for group A and 16 μg/dl for group B (p = 0.4). There were no steroid toxicity differences between groups. Conclusions: The duration of the treatment had an impact on the number of relapses without increasing steroid toxicity.
RESUMEN
BACKGROUND: In the steroid-sensitive nephrotic syndrome (SSNS) the prolonged treatment with steroids could decrease the frequency of relapses. We conducted a comparative study of prolonged steroid scheme and the usual treatment of primary SSNS to assess: the number of patients with relapses, mean time to treatment initiation, to remission and to first relapse, total number of relapses, total cumulative dose of steroids, and the steroid toxicity. METHODS: Patients were divided into two groups: group A (27 patients) received 16-ß-methylprednisolone for 12 weeks, reducing the steroid until week 24. Group B (29 patients) received 16-ß-methylprednisolone for 12 weeks and placebo until week 24. RESULTS: Cumulative incidence rate of relapse (person/years) for group A was of 36/100 and 66/100 for group B (p=0.04). Average elapsed time to first relapse was of 114 days for group A and of 75 days to for group B (p=0.01). The difference in time for initial response to treatment and up to achieve remission between both groups was not significant. Total cumulative relapses were 9 for group A and 17 for group B (p=0.04). Total patients with relapses were 3 for group A and 7 for group B (p=0.17). Cumulative average dose per patient was 5,243mg/m2 for group A and 4,306mg/m2 for group B (p=0.3), and serum cortisol was 14µg/dl for group A and 16µg/dl for group B (p=0.4). There were no steroid toxicity differences between groups. CONCLUSIONS: The duration of the treatment had an impact on the number of relapses without increasing steroid toxicity.
RESUMEN
Introducción: el tratamiento esteroide del síndrome nefrótico cortico sensible (SNCS) puede causar alteraciones del metabolismo mineral, prevenibles con calcio y vitamina D. Se llevó a cabo un estudio de cohortes de tipo retrospectivo longitudinal a lo largo de 36 meses. Objetivos: 1) evaluar la relación entre la Dosis Acumulativa de corticoides (DAC) con la concentración sérica de 25-OH Vitamina D y con el Contenido Mineral Ëseo (CMO); 2) evaluar la relación entre la DAC y el CMO en la Densitometría Mineral Ësea (DMO). Material y métodos: Incluimos a pacientes entre 2 años y 12 años con síndrome nefrótico primario cortico-sensible (SNCS) (primer episodio o síndrome nefrótico recaedor o síndrome nefrótico cortico-dependiente), normotensos, eutróficos y con FG>90ml/min/1.73m2, los cuales se separaron en 3 grupos: GRUPO A: 3 o 6 años (puntaje Z y CMO), edad ósea, PTHi. Resultados: Evaluamos a 29 pacientes, con una edad media de 4,4 años. La DMO se realizó en 11 pacientes y no hubo diferencias significativas entre los grupos (p=0,08). Tampoco hubo diferencias significativas entre la media de la edad cronológica y la edad ósea media media (p 0,3). La prueba T para evaluar la dosis de 25-OH colecalciferol al aumentar la dosis de Ergocalciferol fue significativa (T:32.4 Q: <0.001). Hubo una correlación significativa entre los tres grupos: entre la dosis de Vitamina D y el dosaje sérico de Vitamina D de 0,9; entre el DAC y la dosis de 25 OH colecalciferol de 0,62 y entre el DAC y el CMO de 0.44. Por último, el aumento promedio en los tres grupos de dosis de vitamina D fue de 1833UI. Conclusiones: Observamos una relación entre la DAC e hipovitaminosis D, corregible al aumentar la dosis de Vitamina D.
Introduction: steroid treatment for corticosteroid-sensitive nephrotic syndrome (CSNS) could cause bone and mineral metabolism alterations, preventable with calcium and Vitamin D. Objectives: We carried out a preliminary retrospective study along 36 months with the following objectives. 1) To evaluate the relationship between Cumulative Corticosteroid Doses (CCD) and 25-0 Vitamin D serum concentration and with Bone Mineral Content (BMC); 2) To evaluate the relationship between CCD and Bone Mineral Densitomety (BMD). Methods: We included patients between 2 and 12 years of age with corticosteroid sensitive primary nephrotic syndrome (CSNS) (first episode, relapsing nephrotic syndrome, corticosteroid dependent nephrotic syndrome) normotensive, eutrophic and FG>:90ml/min/1.73 m2, who were divided into three groups: GROUP A: =3 or 4 relapses/year, GROUP C: CSNS, we measured: a) Quarterly: calcemia, phosphatemia, alkaline phosphatase; b) half-yearly: 25-OH cholecalcipherol levels, CCD; c) annually BMD in children >6 years (score Z and BMC), bone age, PTHi. Results: We evaluated 29 patients, average age: 4.4 years. The BMD was performed on 11 patients and there were no significant differences among the groups (p=0.08). No significant differences were seen between chronologic age and average bone age (p=0.3). Change in 25-OH cholecalcipherol levels due to the increase of ergocalcipherol dose was significant (T:32.4 Q:<0.001). There were significant correlation in the three groups, between Vitamin D dose and Vitamin D serum levels (Pearson correlation R=0.9), between CCD and 25 OH cholecalcipherol dose: (Pearson correlation R=0.62) and between CCD and BMC (Pearson correlation R=0.44). Finally, in these three groups the average increase of vitamin D was: 1833IU. Conclusions: We found a relationship between CCD and hypovitaminosis D, which could be corrected increasing Vitamin D dose.
Asunto(s)
Masculino , Femenino , Humanos , Niño , Corticoesteroides , Trastornos del Metabolismo del Calcio , Síndrome Nefrótico , Trastornos del Metabolismo del Fósforo , Vitamina D/uso terapéuticoRESUMEN
UNLABELLED: Idiopathic hypercalciuria may be associated with urinary tract infection, hematuria, nephrolithiasis and osteopenia. In order to describe the occurrence of these concurrent conditions related to the variation in urinary calcium and hypercalciuria response to sequential therapy, with a normal protein and low sodium diet, potassium citrate and hydrochlorothiazide; 46 patients older than 4 years, with no urinary tract diseases, sphincter control and normal blood creatinine values were followed-up during 43 months. Hypercalciuria was seen to be associated with kidney stones (EAR 47%; RR 3.3), hematuria (EAR 71%; RR 2.5), urinary tract infections (EAR 57%; RR 3), and osteopenia (EAR 33%; RR 3). A normal value of urinary calcium was achieved with sequential therapy in 43 patients, but during follow-up 32 patients discontinued treatment and hypercalciuria recurred in 44% of them, in association with hematuria and urinary tract infection. CONCLUSIONS: Sequential therapy reduced hypercalciuria and the incidence of associated diseases.
Asunto(s)
Hipercalciuria/complicaciones , Hipercalciuria/terapia , Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Estudios RetrospectivosRESUMEN
Idiopathic hypercalciuria may be associated with urinary tract infection, hematuria, nephrolithiasis and osteopenia. In order to describe the occurrence of these concurrent conditions related to the variation in urinary calcium and hypercalciuria response to sequential therapy, with a normal protein and low sodium diet, potassium citrate and hydrochlorothiazide; 46 patients older than 4 years, with no urinary tract diseases, sphincter control and normal blood creatinine values were followed-up during 43 months. Hypercalciuria was seen to be associated with kidney stones (EAR 47%; RR 3.3), hematuria (EAR 71%; RR 2.5), urinary tract infections (EAR 57%; RR 3), and osteopenia (EAR 33%; RR 3). A normal value of urinary calcium was achieved with sequential therapy in 43 patients, but during follow-up 32 patients discontinued treatment and hypercalciuria recurred in 44% of them, in association with hematuria and urinary tract infection. Conclusions. Sequential therapy reduced hypercalciuria and the incidence of associated diseases.(AU)
La hipercalciuria idiopática puede asociarse con infección urinaria, hematuria, nefrolitiasis y osteopenia; con los objetivos de describir la aparición de estas patologías concurrentes, relacionadas con la variación del calcio urinario y la respuesta al tratamiento secuencial de la hipercalciuria, con dieta normoproteica-hiposódica, citrato de potasio e hidroclorotiazida, controlamos durante 43 meses a 46 pacientes mayores de 4 años, sin uropatías, con control esfinteriano y creatininemias normales. Observamos que la hipercalciuria se asoció con litiasis renal (RAE 47%; RR 3,3); hematuria (RAE 71%; RR 2,5); infecciones urinarias (RAE 57%; RR 3) y osteopenia (RAE 33%; RR 3). La terapéutica secuencial normalizó el calcio urinario en 43 pacientes, pero durante el seguimiento, 32 interrumpieron el tratamiento y la hipercalciuria reapareció en 44% de ellos, asociada a hematuria e infección urinaria. Conclusiones. El tratamiento secuencial redujo la hipercalciuria y disminuyó la incidencia de patologías asociadas.(AU)
Asunto(s)
Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Hipercalciuria/complicaciones , Hipercalciuria/terapia , Estudios RetrospectivosRESUMEN
Idiopathic hypercalciuria may be associated with urinary tract infection, hematuria, nephrolithiasis and osteopenia. In order to describe the occurrence of these concurrent conditions related to the variation in urinary calcium and hypercalciuria response to sequential therapy, with a normal protein and low sodium diet, potassium citrate and hydrochlorothiazide; 46 patients older than 4 years, with no urinary tract diseases, sphincter control and normal blood creatinine values were followed-up during 43 months. Hypercalciuria was seen to be associated with kidney stones (EAR 47%; RR 3.3), hematuria (EAR 71%; RR 2.5), urinary tract infections (EAR 57%; RR 3), and osteopenia (EAR 33%; RR 3). A normal value of urinary calcium was achieved with sequential therapy in 43 patients, but during follow-up 32 patients discontinued treatment and hypercalciuria recurred in 44% of them, in association with hematuria and urinary tract infection. Conclusions. Sequential therapy reduced hypercalciuria and the incidence of associated diseases.
La hipercalciuria idiopática puede asociarse con infección urinaria, hematuria, nefrolitiasis y osteopenia; con los objetivos de describir la aparición de estas patologías concurrentes, relacionadas con la variación del calcio urinario y la respuesta al tratamiento secuencial de la hipercalciuria, con dieta normoproteica-hiposódica, citrato de potasio e hidroclorotiazida, controlamos durante 43 meses a 46 pacientes mayores de 4 años, sin uropatías, con control esfinteriano y creatininemias normales. Observamos que la hipercalciuria se asoció con litiasis renal (RAE 47%; RR 3,3); hematuria (RAE 71%; RR 2,5); infecciones urinarias (RAE 57%; RR 3) y osteopenia (RAE 33%; RR 3). La terapéutica secuencial normalizó el calcio urinario en 43 pacientes, pero durante el seguimiento, 32 interrumpieron el tratamiento y la hipercalciuria reapareció en 44% de ellos, asociada a hematuria e infección urinaria. Conclusiones. El tratamiento secuencial redujo la hipercalciuria y disminuyó la incidencia de patologías asociadas.
Asunto(s)
Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Hipercalciuria/complicaciones , Hipercalciuria/terapia , Estudios RetrospectivosRESUMEN
UNLABELLED: Idiopathic hypercalciuria may be associated with urinary tract infection, hematuria, nephrolithiasis and osteopenia. In order to describe the occurrence of these concurrent conditions related to the variation in urinary calcium and hypercalciuria response to sequential therapy, with a normal protein and low sodium diet, potassium citrate and hydrochlorothiazide; 46 patients older than 4 years, with no urinary tract diseases, sphincter control and normal blood creatinine values were followed-up during 43 months. Hypercalciuria was seen to be associated with kidney stones (EAR 47
; RR 3.3), hematuria (EAR 71
; RR 2.5), urinary tract infections (EAR 57
; RR 3), and osteopenia (EAR 33
; RR 3). A normal value of urinary calcium was achieved with sequential therapy in 43 patients, but during follow-up 32 patients discontinued treatment and hypercalciuria recurred in 44
of them, in association with hematuria and urinary tract infection. CONCLUSIONS: Sequential therapy reduced hypercalciuria and the incidence of associated diseases.
Asunto(s)
Hipercalciuria/complicaciones , Hipercalciuria/terapia , Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Estudios RetrospectivosRESUMEN
Persistent nephrotic syndrome that does not respond to treatment may cause progression to kidney failure. We designed a therapeutic protocol with sirolimus for this group of patients. We conducted a prospective, interventional, time series, cohort study lasting 20 months. Thirteen patients were enrolled, with a mean age of 10 years (range: 8-18 years old) with steroid-resistant primary nephrotic syndrome and a histological diagnosis of focal and segmental glomerulosclerosis. We administered sirolimus 3.6mg/m2/day. The duration of this regimen was 12 months in responsive patients. The protocol's efficacy was assessed according to reduction of proteinuria (3 response levels: total, partial, or no response). Severity of histological renal damage and mean time from clinical diagnosis to protocol initiation were also assessed. Nine of 13 patients responded to the treatment with sirolimus, and mean progression time and the severity of histological renal damage influenced response to therapy. We believe that sirolimus is a valid treatment option in patients with steroid-resistant nephrotic syndrome, even though this regimen probably requires an earlier treatment.
Asunto(s)
Inmunosupresores/uso terapéutico , Síndrome Nefrótico/tratamiento farmacológico , Sirolimus/uso terapéutico , Adolescente , Corticoesteroides/farmacología , Niño , Estudios de Cohortes , Resistencia a Medicamentos , Femenino , Estudios de Seguimiento , Glomeruloesclerosis Focal y Segmentaria/complicaciones , Glomeruloesclerosis Focal y Segmentaria/patología , Humanos , Inmunosupresores/administración & dosificación , Riñón/patología , Masculino , Síndrome Nefrótico/etiología , Síndrome Nefrótico/patología , Estudios Prospectivos , Proteinuria/tratamiento farmacológico , Proteinuria/etiología , Inducción de Remisión , Sirolimus/administración & dosificación , Resultado del TratamientoRESUMEN
Introducción: Los pacientes adolescentes representan un desafío para el nefrólogo. Aunque la patología renal del mismo se asemeja más a la del adulto, tiene una epidemiología única a considerar. Métodos: Estudio descriptivo, retrospectivo. Se relevaron 43 historias clínicas de pacientes entre 10 Y 18 anos ingresados por primera vez en nefrología entre enero de 2009 y mayo de 2011, analizando datos demográficos, motivo de consulta, lugar de referencia, tiempo entre inicio de síntomas y la referencia al servicio, días de internación, diagnóstico de enfermedad renal y causas de ingreso a diálisis. Resultados: Se internaron 394 pacientes, 136 fueron adolescentes. 43 internaciones de primera vez, y de estos, 24 mujeres. Edad promedio 13,5 años ± 2,37. 27 pacientes de provincia de Bs. As., 11 CABA, y 5 resto del País. 27 derivados desde nuestro propio hospital y 16 de otros centros médicos. Los síntomas y signos más frecuentes fueron hematuria, edemas, proteinuria y disminución del filtrado glornerular. La media entre inido de síntomas y la consulta fue 15 días (rango 1-30). Promedio de días de internación 13,7 (rango 2-95). Las patologías prevalentes fueron las glomerulopatias y la nefropatía lúpica la enfermedad renal más frecuente. 11 pacientes requirieron diálisis, y 9 permanentemente. Conclusiones: Los adolescentes presentan prevalencia patológica diferente a la de pediatría. La presencia de IRCT sin diagnóstico previo fue significativa.(AU)
Introduction: Teenager patients represent a challenge for Nephrologists. Although renal pathology of such patients is similar to adults, it has a unique epidemiology which must be considered. Methods: Retrospective, descriptive study. 43 clinical histories of patients between 10 and 18 years old admitted for the first time in Nephrology division between January 2009 and May 2011 were reported. We analyzed demographic data, consultation cause, reference place, time between the beginning of symptoms and the reference to the division, days of hospitalization, renal disease diagnosis and dialysis admission causes. Results: 394 patients were admitted, 136 were teenagers, 43 admissions for the first time and from these 24 women. Average age 13,5 years old +-2,37.27 patients from Buenos Aires province, 11 Capital City of Buenos Aires and 5 from the rest of the country. 27 referred from our own hospital and 16 from other medical centers. The 139 most frequent symptoms and signs were hematuria, edema, proteinuria and decrease of glomerular filtration. The average between the beginning of symptoms and consultation was 15 days (range1-30). Admission day average 13,7(range 2-95). Prevalent pathologies were glomerulopathies and lupic nephropathy the most frequent renal disease. 11 patients required dialysis. Conclusions: Teenagers show different pathological evidence in comparison to pediatrics. The presence of IRCT without previous diagnosis was significant.(AU)
Asunto(s)
Humanos , Masculino , Adolescente , Femenino , Niño , Enfermedades Renales/epidemiología , Glomerulonefritis/epidemiología , Glomerulonefritis/diagnóstico , PrevalenciaRESUMEN
Introducción: Los pacientes adolescentes representan un desafío para el nefrólogo. Aunque la patología renal del mismo se asemeja más a la del adulto, tiene una epidemiología única a considerar. Métodos: Estudio descriptivo, retrospectivo. Se relevaron 43 historias clínicas de pacientes entre 10 Y 18 anos ingresados por primera vez en nefrología entre enero de 2009 y mayo de 2011, analizando datos demográficos, motivo de consulta, lugar de referencia, tiempo entre inicio de síntomas y la referencia al servicio, días de internación, diagnóstico de enfermedad renal y causas de ingreso a diálisis. Resultados: Se internaron 394 pacientes, 136 fueron adolescentes. 43 internaciones de primera vez, y de estos, 24 mujeres. Edad promedio 13,5 años ± 2,37. 27 pacientes de provincia de Bs. As., 11 CABA, y 5 resto del País. 27 derivados desde nuestro propio hospital y 16 de otros centros médicos. Los síntomas y signos más frecuentes fueron hematuria, edemas, proteinuria y disminución del filtrado glornerular. La media entre inido de síntomas y la consulta fue 15 días (rango 1-30). Promedio de días de internación 13,7 (rango 2-95). Las patologías prevalentes fueron las glomerulopatias y la nefropatía lúpica la enfermedad renal más frecuente. 11 pacientes requirieron diálisis, y 9 permanentemente. Conclusiones: Los adolescentes presentan prevalencia patológica diferente a la de pediatría. La presencia de IRCT sin diagnóstico previo fue significativa.
Introduction: Teenager patients represent a challenge for Nephrologists. Although renal pathology of such patients is similar to adults, it has a unique epidemiology which must be considered. Methods: Retrospective, descriptive study. 43 clinical histories of patients between 10 and 18 years old admitted for the first time in Nephrology division between January 2009 and May 2011 were reported. We analyzed demographic data, consultation cause, reference place, time between the beginning of symptoms and the reference to the division, days of hospitalization, renal disease diagnosis and dialysis admission causes. Results: 394 patients were admitted, 136 were teenagers, 43 admissions for the first time and from these 24 women. Average age 13,5 years old +-2,37.27 patients from Buenos Aires province, 11 Capital City of Buenos Aires and 5 from the rest of the country. 27 referred from our own hospital and 16 from other medical centers. The 139 most frequent symptoms and signs were hematuria, edema, proteinuria and decrease of glomerular filtration. The average between the beginning of symptoms and consultation was 15 days (range1-30). Admission day average 13,7(range 2-95). Prevalent pathologies were glomerulopathies and lupic nephropathy the most frequent renal disease. 11 patients required dialysis. Conclusions: Teenagers show different pathological evidence in comparison to pediatrics. The presence of IRCT without previous diagnosis was significant.
Asunto(s)
Humanos , Masculino , Adolescente , Femenino , Niño , Enfermedades Renales/epidemiología , Glomerulonefritis/epidemiología , Glomerulonefritis/diagnóstico , PrevalenciaRESUMEN
Estudio descriptivo de una serie de casos de 12 pacientes no consanguíneos: 6 pares de hermanos de entre 2 y 16 años. Cinco de estos pares de hermanos carecían de antecedentes familiares de nefropatías; y un par presentaba antecedente materno de insuficiencia renal crónica terminal secundaria a síndrome nefrótico corticorresistente.
Asunto(s)
Humanos , Masculino , Adolescente , Niño , Femenino , Fallo Renal Crónico/prevención & control , Salud Infantil , Síndrome Nefrótico/diagnóstico , Síndrome Nefrótico/genética , Síndrome Nefrótico/terapiaRESUMEN
INTRODUCTION: The patient with a solitary kidney and free protein intake can present pathological microalbuminuria. OBJECTIVE: To evaluate the efficacy of Enalapril in patients with single kidney and with or without normoprotein diet. MATERIALS AND METHODS: We studied 49 patients, mean age 11 years, eutrophics, with normal renal function and with approved medical consent. The exclusion criteria were: uropathies, arterial hypertension, malignant diseases, orthostatic proteinuria and previous treatments with nephrotoxics drugs. Patients were classified in two groups: Group A: with normoprotein diet (0.8 to 1.2 g/kg/day). Group B: with free protein intake. The patients with abnormal microalbuminuria received Enalapril (doses between 0.1-0.3 mg/kg/ day). RESULTS: Group A: 21 patients, 2 with abnormal microalbuminuria. Mean increase of the renal size 14% (SD 8), risk of presenting pathological microalbuminuria: 9%. Group B: 28 patients, 11 with pathological microalbuminuria. Mean increase of the renal size: 33.8% (SD 6.1), risk of presenting abnormal microalbuminuria: 40%. RR: 4.125 (CI 1-16) (p: 0.01). NND: 3. Mean range of microalbuminuria pre- Enalapril 50 microg/min and post-Enalapril 11 microg/ min. Mean doses of Enalapril: 0.2 mg/kg/day. Correlation coefficient between increase of renal size and microalbuminuria range: 0.75 and between increase renal size and protein intake: 0.72. Mean time to reach abnormal microalbuminuria: 81 months (DS 7). CONCLUSION: Enalapril together with the normoprotein diet in patient with single kidney reduces the risk of developing abnormal microalbuminuria.
Asunto(s)
Albuminuria/tratamiento farmacológico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Proteínas en la Dieta , Enalapril/uso terapéutico , Adolescente , Niño , Femenino , Humanos , Riñón , Masculino , Estudios RetrospectivosRESUMEN
El paciente monorreno, sin dieta normoproteica,puede presentar microalbuminuriaanormal con eventual desarrollo de glomerulosclerosis.Objetivo. Evaluar la eficacia del Enalapril parareducir la microalbuminuria patológica en pacientesmonorrenos con dieta normoproteica y sin ella.Población, material y métodos. Estudiamos 49 pacientesmonorrenos, edad (media) 11 años, eutróficos,con función renal normal y consentimiento médicoaprobado. Criterios de exclusión: uropatías,hipertensión arterial, enfermedades oncológicas, tratamientoscon drogas nefrotóxicas, proteinuriaortostática. La población se clasificó en dos grupos:Grupo A: con dieta normoproteica (0,8-1,2 g/kg/díapara sexo y edad). Grupo B: con dieta libre.A los pacientes con microalbuminuria anormal seles administró Enalapril (intervalo de dosis: 0,1 mg/kg/día a 0,3 mg/kg/día).Resultados. Grupo A: 21 pacientes, 2 con microalbuminuriapatológica. Aumento promedio del tamañorenal: 14% (DE 8 por ciento). Riesgo de presentarmicroalbuminuria patológica: 9 porc ciento.Grupo B: 28 pacientes, 11 con microalbuminuriaanormal. Riesgo de presentar microalbuminuriaanormal: 40 por ciento. Aumento promedio del tamaño renal:33,8 (DE 6,1 por ciento). RR: 4,125(IC 1-16) (p: 0,01).NND: 3. Media de microalbuminuria pre-Enalapril50,20 μg/minuto y post-Enalapril 11,5 μg/minuto.Dosis media de Enalapril: 0,2 mg/kg/día.Coeficiente de correlación entre microalbuminuriay aumento del tamaño renal: 0,75; y entre ingestaproteica y aumento del tamaño renal: 0,72.Tiempo (medio) de aparición de la microalbuminuriaanormal: 81 meses (DE 7 meses).Conclusión. El Enalapril junto con la dieta normoproteicaen pacientes monorrenos disminuyen elriesgo de desarrollar microalbuminuria anormal